ClinicalTrials.gg
CompletedNCT02762955CALYPSOUpdated Sep 8, 2021

Comparative Clinical Trial of Efficacy and Safety of BCD-057 and Humira® in Patients With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of BCD-057 and Humira® in Psoriasis, sponsored by Biocad. Completed at 1 site in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2021-09-08.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies testing adalimumab in Psoriasis — 6 open to participants now, 6 under way, 1 of them phase 3. Adalimumab · Psoriasis.

Enrollment
13th of 48
344 · median 148
Started
2016
with 2 others
Phase 3
26 of 48
1 open now
Registered
35th of 48
by date
Lead sponsor
1 of 48
Biocad

Among the 48 studies testing adalimumab in Psoriasis, this one is the 13th largest by enrollment, is one of 3 that started in 2016, is one of 26 in phase 3, and was the 35th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

6 of the 48 studies testing adalimumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies testing adalimumab in Psoriasis, or all of them as a file.
02

Study summary

CALYPSO clinical study is a phase 3 study which is carried out to establish the efficacy, safety and pharmacokinetic equivalence of BCD-055 (adalimumab, manufactured by JSC BIOCAD, Russia) and Humira® when used in patients with moderate to severe plaque psoriasis.

Read the detailed description

CALYPSO study is the next step of clinical evaluation of adalimumab biosimilar manufactured by joint-stock company (JSC) BIOCAD, Russia.The aim of this study is to establish that BCD-057 is equivalent to Humira® in terms of efficacy, safety and pharmacokinetics when used by the standard regimen in patients with plaque psoriasis.

The study will enroll 344 patients with moderate to severe plaque psoriasis, who will be randomized into 2 groups (1:1 ratio): patients from the first group will receive BCD-057 subcutaneously (SC) at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Then participants of this group will be invited for randomization at week 25 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). Patients will continue to receive 40 mg of BCD-057 on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.

Patients from the second group will receive Humira® subcutaneously (SC) at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. At week 25 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057.They will receive Humira® or BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51.

03

Conditions studied

  • Psoriasis

Browse trials for

Keywords

  • adalimumab
  • biosimilar
  • BCD-057
  • psoriasis
  • tumor necrosis factor
  • monoclonal antibody
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient had written .
  • Age between 18 and 75 years.
  • Patient has moderate to severe plaque psoriasis with stable course of the disease for 6 months
  • Patient has had at least 1 course of phototherapy or systemic treatment for psoriasis or are candidates for such treatment in opinion of Investigator.
  • BSA affected by psoriasis ≥ 10%, PASI score ≥ 12, sPGA score ≥ 3.
  • Patient has ≥ 10 g/dl, leucocytes count ≥ 3 000/mcl, count ≥ 100 000/mcl, ≥ 2 000/mcl, , alanine aminotransferase and alkaline phosphatase exceed 2,5 or less times the creatinine less than 176,8 µmol/l, no serologic or virologic markers of virus and virus, negative urine pregnancy test, no signs of tuberculosis (negative tuberculosis skin test or negative quantiferon test. Patients can be included in they have positive tuberculin test, have had Bacteria Calmette-Guerin (BCG) vaccination and have negative Diaskintest or negative quantiferon test. Patients can be included if they have positive tuberculin test, have not been vaccinated with BCG and also patients with positive or uncertain quantiferon test/Diaskintest if they have documented adequate prophylaxis of tuberculosis finished before first adalimumab injection AND have documented absence of contacts with patients who have active tuberculosis AND have no signs of tuberculosis on chest X-Ray that was performed during 3 months before randomization)
  • Patients are able to perform all procedures planed by protocol.
  • Patients are ready for with reliable methods starting 2 weeks before entering the study, and up to 4 weeks after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Subject diagnosed with erythrodermic psoriasis, pustular psoriasis, guttate psoriasis, medication-induced psoriasis, or other skin conditions at the time of the screening visit (e.g., eczema) that would interfere with evaluations of the effect of product on psoriasis.
  • Previous receipt of adalimumab, history of use of any other biological anti-tumor necrosis factor-alpha therapy. Prior use of two or more biologics for treatment of psoriasis.
  • Previous receipt of monoclonal antibodies if they were cancelled less that in 12 weeks before screening
  • Patient is taking for up to 4 weeks before signing and during screening, disease-modifying drugs including methotrexate, sulfasalazin and cyclosporin for up to 4 weeks before signing informed consent, leflunomide, cyclophosphamide for up to 6 months before signing informed consent, phototherapy including selective phototherapy and photochemotherapy for up to 4 weeks before signing informed consent, live or attenuated vaccines for up to 8 weeks before signing informed consent.
  • Subject cannot discontinue systemic therapies and/or topical therapies for the treatment of psoriasis and cannot avoid phototherapy.
  • Subject has a planned surgical intervention during the study or had surgical intervention less than 30 days prior to study.
  • Subject has an active infection or history of infections as follows: any active infection for which systemic anti-infectives were used within 28 days prior to signing informed consent; a serious infection, defined as requiring hospitalization or intravenous anti-infectives within 8 weeks prior to signing informed consent; recurrent or chronic infections or other active infection that, in the opinion of the Investigator, might cause this study to be detrimental to the subject.
  • Subject has known history of or any other severe immunodeficiency.
  • surface antigen or Hepatitis B core antigen or antibody positivity at screening.
  • History of tuberculosis.
  • Positive results of rapid plasma reagin-test for T.pallidum at screening.
  • Active ongoing diseases other than psoriasis that might confound the evaluation of the benefit of treatment of adalimumab or can increase risk of adverse reactions: acute inflammatory diseases or exacerbation of chronic diseases otherwise than psoriasis; stable ischemic heart disease III-IV functional class, unstable angina or history of myocardial infarction less than 1 year before the signing of informed consent; moderate to severe heart failure ( [NYHA] class III/IV; severe resistant arterial hypertension, atopic bronchial asthma, history of angiooedema, moderate to severe respiratory insufficiency, chronic obstructive lung disease 3-4 grade, decompensated diabetes mellitus, systemic diseases, active neurologic disorders or their symptoms, other underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the patient and/or places the patient at unacceptable risk for receiving an immunomodulatory therapy.
  • Subject has history of within 5 years EXCEPT treated and considered cured cutaneous squamous or basal cell carcinoma, in situ cervical cancer, OR in situ breast ductal carcinoma.
  • Subject has a history of to the active substance or to any of the of adalimumab or BCD-057 or other monoclonal antibodies.
  • Female subject who is pregnant or breast-feeding or considering becoming pregnant during the study.
  • Subject has any mental illness, including severe depressive disorders and / or suicidal thoughts in history, which, in the opinion of the investigator, may create excessive risk to the patient or to influence the patient's ability to follow the protocol.
  • History of drug addiction, alcoholism.
  • Simultaneous participation in any other clinical trial, as well as former participation in other clinical trials within 3 months before this study initiation; previous participation in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
344 participants (actual)

Study arms

  • Experimental
    BCD-057 group

    BCD-057 group includes patients with moderate to severe plaque psoriasis, who will receive BCD-057 subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21 and 23. Patients will be invited for randomization at week 24 (in order to keep the double-blind design of the study), but it will have a formal character (assignment of a new randomization number and lot). From week 25 patients of this group will continue to receive BCD-057 at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51. BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa.

    Biological: BCD-057

  • Active comparator
    Humira® group

    Humira® group includes patients with moderate to severe plaque psoriasis, who will receive Humira® subcutaneously at a dose 80 mg on week 0, then at a dose 40 mg on weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23. At week 24 participants will re-randomized (1:1) to treatment with Humira® or will transitioned to BCD-057. Patients will receive BCD-057 or Humira® at a dose 40 mg on weeks 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49 and 51. BCD-057 is adalimumab biosimilar, monoclonal antibody to tumor necrosis factor alfa. Humira® is original drug of adalimumab, monoclonal antibody to tumor necrosis factor alfa.

    Biological: Humira®

Interventions

  • BiologicalBCD-057

    BCD-057 is biosimilar of adalimumab (produced by BIOCAD).

    Also known as: adalimumab

  • BiologicalHumira®

    Humira is the original adalimumab (produced by F. Hoffman-La Roche)

    Also known as: adalimumab

06

What researchers measure

Primary outcomes

  1. Ratio of patients with PASI75 response after 16 weeks of therapy

    Ratio of patients who developed a decrease in Psoriasis Area Severity Index score by 75% or more (PASI75) after 16 weeks of therapy with adalimumab vs. baseline.

    Time frame: 16 weeks of therapy

Secondary outcomes

  1. PASI Improvement (%) after 16, 24, 33 and 55 weeks of therapy with adalimumab.

    Percent improvement in Psoriasis Area Severity Index (PASI) after 16, 24, 33 and 55 weeks of therapy with adalimumab.

    Time frame: 16, 24, 33 and 55 weeks of therapy

  2. Ratio of patients with PASI75 response after 24, 33, 55 weeks of therapy

    Ratio of patients who developed a decrease in Psoriasis Area Severity Index score by 75% or more (PASI75) after 33, 55 weeks of therapy with adalimumab vs. baseline.

    Time frame: 24, 33 and 55 weeks of therapy

  3. Ratio of patients with PASI50 and PASI90 response after 16, 33, 55 weeks of therapy.

    Ratio of patients who developed a decrease in Psoriasis Area Severity Index score by 50% or more (PASI50) and Psoriasis Area Severity Index score by 90% or more (PASI90) after 16, 24, 33, 55 weeks of therapy with adalimumab vs. baseline.

    Time frame: 16, 24, 33 and 55 weeks of therapy

  4. Ratio of patients with sPGA response after 16, 33, 55 weeks of therapy

    Ratio of patients who have Physicians Global Assessment (sPGA) score 0 or 1 after 16, 33, 55 weeks of therapy with adalimumab.

    Time frame: 16, 24, 33 and 55 weeks of therapy

  5. BSA Improvement (%) after 16, 24, 33, 55 weeks of therapy

    Percent of body surface area (BSA), affected by psoriasis (measured by physician during physical examination of patient), after 16, 33, 55 weeks of therapy with adalimumab vs. baseline.

    Time frame: 16, 24, 33 and 55 weeks of therapy

  6. Change in SF-36

    Change in Short Form-36 questionnaire (SF-36) from Week 0 to Week 16 and from Week 16 to Week 55.

    Time frame: Week 0 to Week 16; Week 16 to Week 55

  7. Change in DQLI

    Change in Dermatology Quality of Life Index questionnaire (DLQI) from Week 0 to Week 16 and from Week 16 to Week 55.

    Time frame: Week 0 to Week 16; Week 16 to Week 55

  8. Adverse events (AE) severity and frequency related to adalimumab

    Time frame: 16 and 55 weeks of therapy

  9. Overall adverse events (AE) and serious adverse events (SAE) frequency

    Time frame: 16 and 55 weeks of therapy

  10. Frequency of early withdrawal due to AE/SAE

    Time frame: 16 and 55 weeks of therapy

  11. Ratio of patients with binding and neutralizing antibodies to adalimumab

    Time frame: 55 weeks

  12. AUC(0-tau) of adalimumab after multiple adalimumab injections

    Area under the plasma concentration versus time curve (AUC) 0-tau of adalimumab after multiple adalimumab injections

    Time frame: 55 weeks

  13. Cav,ss of adalimumab after multiple adalimumab injections

    Average blood concentration of adalimumab in steady state conditions (Cav,ss)

    Time frame: 55 weeks

  14. Т½ of adalimumab after multiple adalimumab injections

    Half-life (Т½) of adalimumab after multiple adalimumab injections

    Time frame: 55 weeks

  15. Vd of adalimumab after multiple adalimumab injections

    Volume of distribution (Vd) of adalimumab after multiple adalimumab injections

    Time frame: 55 weeks

  16. Cl of adalimumab after multiple adalimumab injections

    Clearance (Cl) of adalimumab after multiple adalimumab injections

    Time frame: 55 weeks

07

Study locations

1 site
  • BIOCAD
    Saint Petersburg, Strelna 198515, Russian Federation
08

References and documents

Publications

  • Samtsov AV, Bakulev AL, Khairutdinov VR, Kokhan MM, Korotaeva TV, Minullin IK, Vylegzhanina OA, Dubenskiy VV, Khalilov BV, Khotko AA, Zykova OS, Chumachenko IV, Lukyanov AM, Artemeva AV, Pukhtinskaia PP. Long-term data on the proposed adalimumab biosimilar BCD-057 in patients with moderate to severe psoriasis: A randomized controlled trial. PLoS One. 2022 Feb 7;17(2):e0263214. doi: 10.1371/journal.pone.0263214. eCollection 2022. PubMed 35130291 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Dec 2017, 12 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 12 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
May 5, 2016
StartActual
Dec 2016
Primary completionActual
Dec 2017
CompletionActual
Oct 15, 2018
Last update
Sep 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02762955
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
May 5, 2016
Start date
Dec 2016
Primary completion
Dec 2017
Completion
Oct 15, 2018
Last update
Sep 8, 2021

Study contacts

Roman Ivanov, PhD
study chair · JCS BIOCAD

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Adalimumab

Start the discussion